Skip to main content

Advertisement

SpringerLink
Log in

XPD Asp312Asn polymorphism is a risk factor for prostate cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The association between Asp312Asn and Lys751Gln polymorphisms of Xeroderma pigmentosum Group D (XPD) and prostate cancer risk are still inconclusive. For better understanding of the effects of these two polymorphisms on prostate cancer risk, a meta-analysis was performed.

Methods

An extensive search was performed to identify all case–control studies investigating such association. The strength of association between these two polymorphisms and prostate cancer risk was assessed by odds ratio (OR) with the corresponding 95 % confidence interval (95 % CI).

Results

A total of seven case–control studies were identified, among which five studies (1,257 cases and 1,956 controls) were eligible for Asp312Asn polymorphism and six studies (1,451 cases and 2,375 controls) were eligible for Lys751Gln polymorphism. Asp312Asn polymorphism was associated with an increased risk of prostate cancer in additive and recessive genetic models (additive model: OR = 1.68, 95 % CI = 1.28–2.22, P = 0.00; recessive model: OR = 1.65, 95 % CI = 1.27–2.15, P = 0.00). In the subgroup analysis, Asp312Asn polymorphism was associated with an increased risk of prostate cancer among Asians in all three genetic models (additive model: OR = 2.09, 95 % CI = 1.39–3.14, P = 0.00; dominant model: OR = 1.49, 95 % CI = 1.12–1.98, P = 0.01; recessive model: OR = 1.93, 95 % CI = 1.31–2.83, P = 0.00). However, no significant associations were found between Lys751Gln polymorphism and prostate cancer risk in the overall analyses or the subgroup analyses by ethnicity.

Conclusions

The results of this meta-analysis indicate that the XPD Asp312Asn polymorphism is a risk factor for prostate cancer development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Bau DT, Wu HC, Chiu CF et al (2007) Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res 27:2893–2896

    PubMed  CAS  Google Scholar 

  • Benhamou S, Sarasin A (2005) ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 161:1–14

    Article  PubMed  Google Scholar 

  • Brewster AM, Alberg AJ, Strickland PT, Hoffman SC, Helzlsouer K (2004) XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 13:1271–1275

    PubMed  CAS  Google Scholar 

  • Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129

    Article  Google Scholar 

  • DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  • Dhillon VS, Yeoh E, Fenech M (2011) DNA repair gene polymorphisms and prostate cancer risk in South Australia–results of a pilot study. Urol Oncol 29:641–646

    Article  PubMed  CAS  Google Scholar 

  • Ding DP, Ma WL, He XF, Zhang Y (2012) XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies. Mol Biol Rep 39:2533–2540

    Article  PubMed  CAS  Google Scholar 

  • Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  • Friedberg EC (2003) DNA damage and repair. Nature 421:436–440

    Article  PubMed  Google Scholar 

  • Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11:1513–1530

    PubMed  CAS  Google Scholar 

  • Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  Google Scholar 

  • Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61

    Article  PubMed  CAS  Google Scholar 

  • Itin PH, Sarasin A, Pittelkow MR (2001) Trichothiodystrophy: update on the sulfur-deficient brittle hair syndromes. J Am Acad Dermatol 44:891–920

    Article  PubMed  CAS  Google Scholar 

  • Kiltie AE (2009) Molecular epidemiology of DNA repair genes in bladder cancer. Methods Mol Biol 472:281–306

    Article  PubMed  CAS  Google Scholar 

  • Lavender NA, Komolafe OO, Benford M et al (2010) No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate 70:113–119

    PubMed  CAS  Google Scholar 

  • Mandal RK, Gangwar R, Mandhani A, Mittal RD (2010) DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India. DNA Cell Biol 29:183–190

    Article  PubMed  CAS  Google Scholar 

  • Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    PubMed  CAS  Google Scholar 

  • Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H (2010) Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer. Breast Cancer Res Treat 124:531–541

    Article  PubMed  CAS  Google Scholar 

  • Ritchey JD, Huang WY, Chokkalingam AP et al (2005) Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 14:1703–1709

    Article  PubMed  CAS  Google Scholar 

  • Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS (2004) DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 13:23–29

    Article  PubMed  CAS  Google Scholar 

  • Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604–608

    PubMed  CAS  Google Scholar 

  • Sobti RC, Berhane N, Melese S et al (2012a) Impact of XPD gene polymorphism on risk of prostate cancer on north Indian population. Mol Cell Biochem 362:263–268

    Article  PubMed  CAS  Google Scholar 

  • Sobti RC, Kaur S, Sharma VL, Singh SK, Hosseini SA, Kler R (2012b) Susceptibility of XPD and RAD51 Genetic Variants to Carcinoma of Urinary Bladder in North Indian Population. DNA Cell Biol 31:199–210

    Article  PubMed  CAS  Google Scholar 

  • Synowiec E, Stefanska J, Morawiec Z, Blasiak J, Wozniak K (2008) Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients. Mutat Res 648:65–72

    Article  PubMed  CAS  Google Scholar 

  • Taylor EM, Broughton BC, Botta E et al (1997) Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc Natl Acad Sci U S A 94:8658–8663

    Article  PubMed  CAS  Google Scholar 

  • Weber CA, Salazar EP, Stewart SA, Thompson LH (1990) ERCC2: cDNA cloning and molecular characterization of a human nucleotide excision repair gene with high homology to yeast RAD3. EMBO J 9:1437–1447

    PubMed  CAS  Google Scholar 

  • Weeda G, Hoeijmakers JH (1993) Genetic analysis of nucleotide excision repair in mammalian cells. Semin Cancer Biol 4:105–117

    PubMed  CAS  Google Scholar 

  • Weiss JM, Goode EL, Ladiges WC, Ulrich CM (2005) Polymorphic variation in hOGG1 and risk of cancer: a review of the functional and epidemiologic literature. Mol Carcinog 42:127–141

    Article  PubMed  CAS  Google Scholar 

  • Zhang J, Qiu LX, Leaw SJ, Hu XC, Chang JH (2011a) The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects. Med Oncol 28:655–660

    Article  PubMed  CAS  Google Scholar 

  • Zhang Y, Ding D, Wang X, Zhu Z, Huang M, He X (2011b) Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies. Int J Colorectal Dis 26:1257–1264

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Oncology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, People’s Republic of China

    Shao-Guang Liao, Lu Liu, Ying Wang, Ying-Yi Zhang & Ya-Jie Wang

Authors
  1. Shao-Guang Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying-Yi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ya-Jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ya-Jie Wang.

Additional information

Shao-Guang Liao and Lu Liu equally contributed to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liao, SG., Liu, L., Wang, Y. et al. XPD Asp312Asn polymorphism is a risk factor for prostate cancer. J Cancer Res Clin Oncol 138, 1689–1695 (2012). https://doi.org/10.1007/s00432-012-1246-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-012-1246-7

Keywords

Search

Navigation